# Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

> **NCT06289673** · PHASE4 · RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 850 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Mixed Phenotype Acute Leukemia

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Vincristine
- **DRUG:** Daunorubicin
- **DRUG:** Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
- **DRUG:** Methotrexate
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT06289673
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-26
- **Primary completion:** 2034-05
- **Final completion:** 2039-05
- **Target enrollment:** 850 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06289673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06289673, "Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06289673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*